Charles River Laboratories International CEO Sells $8,200,513 in Stock (CRL)
Charles River Laboratories International (NYSE:CRL) CEO James Foster sold 174,479 shares of Charles River Laboratories International stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $47.00, for a total value of $8,200,513.00. Following the transaction, the chief executive officer now directly owns 366,580 shares in the company. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of analysts have recently weighed in on CRL shares. Analysts at Robert W. Baird raised their price target on shares of Charles River Laboratories International (NYSE:CRL) from $50.00 to $52.00 in a research note to investors on Monday, August 26th. They now have an “outperform” rating on the stock. Separately, analysts at Jefferies Group raised their price target on shares of Charles River Laboratories International (NYSE:CRL) from $52.00 to $57.00 in a research note to investors on Wednesday, August 7th. They now have a “buy” rating on the stock. Finally, analysts at Goldman Sachs Group Inc. reiterated a “sell” rating on shares of Charles River Laboratories International (NYSE:CRL) in a research note to investors on Tuesday, July 23rd. They now have a $38.00 price target on the stock.
Three analysts have rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $46.05.
Charles River Laboratories International (NYSE:CRL) traded up 0.69% during mid-day trading on Wednesday, hitting $48.15. 217,105 shares of the company’s stock traded hands. Charles River Laboratories International has a 1-year low of $35.54 and a 1-year high of $48.73. The stock has a 50-day moving average of $46.72 and a 200-day moving average of $43.93. The company has a market cap of $2.362 billion and a P/E ratio of 24.80.
Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.73 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.71 by $0.02. The company had revenue of $294.40 million for the quarter, compared to the consensus estimate of $293.77 million. During the same quarter in the prior year, the company posted $0.75 earnings per share. The company’s quarterly revenue was up 3.4% on a year-over-year basis. Analysts expect that Charles River Laboratories International will post $2.84 EPS for the current fiscal year.
Charles River Laboratories International, Inc is a global provider of solutions, which accelerate the early-stage drug discovery and development process.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.